New hope to keep advanced ovarian cancer at bay
NCT ID NCT06121401
Summary
This study aims to confirm how well a two-drug maintenance treatment works to control advanced ovarian cancer after initial chemotherapy. It will involve about 190 women whose cancer has a specific genetic marker (HRD-positive) and who responded to first-line treatment. The goal is to see if taking olaparib pills alongside bevacizumab infusions can help keep the cancer from returning for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, OVARIAN EPITHELIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Socio Sanitaria Territoriale (ASST) Lariana
San Fermo della Battaglia, Como, 22042, Italy
-
Istituto Oncologico Veneto IRCCS
Padua, Italy, 35128, Italy
Conditions
Explore the condition pages connected to this study.